BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heinen A, Schnabel A, Brück N, Smitka M, Wolf C, Lucas N, Dollinger S, Hahn G, Günther C, Berner R, Lee-kirsch M, Schuetz C. Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology 2021;60:e136-8. [DOI: 10.1093/rheumatology/keaa657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J, Zou L, Xu Y, Xu X. Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr 2022;10:962585. [DOI: 10.3389/fped.2022.962585] [Reference Citation Analysis]
2 Tanboon J, Nishino I. Update on dermatomyositis. Curr Opin Neurol 2022. [PMID: 35942671 DOI: 10.1097/WCO.0000000000001091] [Reference Citation Analysis]
3 Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol 2022. [PMID: 35209781 DOI: 10.1080/1744666X.2022.2047022] [Reference Citation Analysis]
4 Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol 2021;33:371-7. [PMID: 34230439 DOI: 10.1097/BOR.0000000000000816] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Rodríguez-Tejero A, López-Espadafor B, Montero-Vílchez T, Sánchez-Díaz M, Arias-Santiago S, Molina-Leyva A. Treatment challenges in clinically amyopathic dermatomyositis: A case series and review of new therapeutic options for skin involvement. Dermatol Ther 2021;34:e14942. [PMID: 33719170 DOI: 10.1111/dth.14942] [Cited by in F6Publishing: 1] [Reference Citation Analysis]